Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8750317 | 0.75 | MEN1 (0.37) | MEN1KMT2ALMNA | |
| SCHEMBL6612249 | 0.70 | ALDH1A1 (0.46) | MEN1KMT2AL3MBTL1LMNAGAA | |
| SCHEMBL6611523 | 0.69 | PKM (0.33) | L3MBTL1LMNA | |
| SCHEMBL12339028 | 0.67 | TSHR (0.36) | MEN1KMT2AL3MBTL1LMNAGAA | |
| SCHEMBL11713104 | 0.66 | MEN1 (0.41) | MEN1KMT2AL3MBTL1LMNAGAA | |
| SCHEMBL1871186 | 0.66 | MEN1 (0.41) | MEN1KMT2AL3MBTL1LMNAGAA | |
| SCHEMBL11713106 | 0.66 | MEN1 (0.41) | MEN1KMT2AL3MBTL1LMNAGAA | |
| SCHEMBL27792891 | 0.66 | MEN1 (0.41) | MEN1KMT2AL3MBTL1LMNAGAA | |
| SCHEMBL6819727 | 0.64 | TYR (0.38) | MEN1KMT2ALMNAGAATDP1 | |
| SCHEMBL2145329 | 0.64 | TSHR (0.57) | L3MBTL1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0765331-A1 | OXABOROLES AND SALTS THEREOF, AND THEIR USE AS BIOCIDES | ZENECA LIMITED (GB) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995033754-A1 | OXABOROLES AND SALTS THEREOF, AND THEIR USE AS BIOCIDES | ZENECA LIMITED (GB) | 1995-12-14 | — | — | WO | disclosed |